查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1518888

神经退化性疾病的分子诊断：技术成长机会，2024-2028

Molecular Diagnostics for Neurodegenerative Diseases: Technology Growth Opportunities, 2024-2028
出版日期: | 出版商: Frost & Sullivan | 英文 106 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

多组体学整合诊断和照护现场诊断的使用是推进神经退化性疾病分子诊断最有前景的成长机会。

神经退化性疾病(NDD) 为医疗保健系统带来了重大挑战，影响着全世界数百万人，因此早期发现至关重要。目前的诊断策略主要是脑部成像技术，但这要等到症状变得更加明显时才会进行。神经元在早期进展过程中发生的微妙变化在与 NDD 相关的结构和功能变化中是无法检测到的。

这项研究是一项综合分析，探讨了 NDD 分子诊断的技术进步、产业动态、策略见解和成长机会。它捕捉了行业内具有创新产品系列的领先企业、成长中的新兴企业和中小企业的作用、关键驱动因素和阻碍因素以及战略合作伙伴关係。我们也深入资金筹措、津贴、併购(M&A) 和商业化工作。

总体而言，本研究的目的是深入了解 NDD 分子诊断的演变及其对医疗保健创新和患者照护的影响。

本次调查回答的关键问题

1.NDD有哪些分子诊断药物可供选择？

2. 与诊断影像相比，广泛采用分子诊断的主要挑战和复杂性是什么？

3.NDD中使用的生物标记的主要讯息是什么？谁是该领域创新和技术的关键和新兴参与者？

4.体学技术、智慧 PoC 设备和胞外体介导的诊断如何成为 NDD 的新分子诊断？他们如何提高准确性？

5.学术界和工业界的联合研究和併购有何战略意义？

6. 专利如何促进 NDD 诊断和治疗方法的进步？

7. NDD 分子诊断存在哪些成长机会？

目录

战略问题

  • 为什么成长如此困难？
  • The Strategic Imperative 8（TM）
  • 神经退化性疾病分子诊断产业三大策略问题的影响
  • 成长机会推动Growth Pipeline Engine（TM）
  • 调查方法

成长机会分析

  • 2050 年失智症疾病负担预测
  • NDD 研究洞察：2019-2024 年出版品和临床试验趋势
  • NDD：概述和早期诊断的重要性
  • 分割
  • NDD 早期诊断的挑战
  • 目前 NDD 的诊断方式
  • NDD分子生物标记的来源
  • 分析范围
  • NDD 诊断：生物标记来源、样本萃取和分析物
  • 生物标记来源：比较分析
  • NDD生物标誌物的综合视角

成长要素

  • 生长促进因子
  • 成长抑制因素

技术分析：脑脊髓液生物标记

  • 基于脑脊髓液的 NDD 分子诊断剂
  • 开发基于 CSF 的 NDD 分子诊断的主要公司
  • 神经诊断的关键生物标记：基于脑脊髓液的生物标记物，全球，2024 年

技术分析：血液生物标记

  • NDD 诊断中的血液生物标记
  • 开发 NDD 血液分子诊断的主要公司
  • 新兴企业开发基于血液的分子诊断以治疗顽固性神经系统疾病
  • 神经诊断的关键生物标记：基于血液的生物标记，全球，2024 年

技术分析：唾液生物标记

  • 唾液生物标记：一种方便且痛苦较小的 NDD 诊断方法
  • 新兴企业开发基于唾液的 NDD 分子诊断

技术分析：尿液生物标记

  • 用于早期诊断 NDD 的尿液生物标记物
  • 开发基于尿液的 NDD 分子诊断的新兴企业

技术分析：眼部生物标记

  • 眼部生物标记：NDD 诊断的新领域
  • 神经生物标记眼部区域的分子变化
  • 开发基于眼科的 NDD 分子诊断的新兴企业

技术分析：基于皮肤的生物标记

  • NDD 皮肤生物标记物

NDD分子诊断关键生物标记概述

  • NDD 诊断领域产业参与者对生物标记物利用的重要见解
  • 从分子生物标记实验室到临床的影响分析

临床试验分析

  • NDD 分子诊断的着名临床试验
  • 欧洲神经退化性疾病平台 (EPND)：资料和样本共用的协作方法

NDD分子诊断新趋势

  • 用于 NDD 诊断中生物标记发现的资料库和生物库催化剂
  • 表观遗传变化作为 NDD 生物标记
  • 利用巨量资料进行 NDD 诊断的多组体学
  • 胞外体：早期 NDD 诊断的潜在候选者
  • 携带式分子诊断设备，实现NDD智慧诊断

主要参与者的策略建议

  • Synaps Dx，美国
  • 法国AgenT生技公司
  • 乌尔沃格尔比欧, 印度
  • 美国共振
  • 纽德克斯，美国

相关人员倡议

  • 着名的 NDD Diagnostics 研究合作和临床联盟
  • NDD 诊断公司最近的併购
  • 全球公司和地区对 NDD 诊断的采用情况

资金筹措分析

  • 2019-2024 年美国NDD 分子诊断公共资金概况
  • NIH 对 AD 分子诊断的资助，2019-2024
  • 欧盟研发计划，2019-2023
  • 2021-2024 年 NDD 分子诊断私人资金筹措概况
  • 2020-2023 年 NDD 分子诊断私人资金筹措概况

专利分析

  • 2019-2024年分子神经生物标记产业智慧财产权趋势
  • 2019-2024 年 NDD 诊断领域主要参与企业的专利
  • 2019-2024年分子神经生物标记产业智慧财产权趋势分析

分析师的观点

  • NDD 中的分子诊断：技术、创新和应用的影响分析
  • NDD 背景下各种分子诊断技术的商业性可用性
  • NDD的分子诊断：技术蓝图

成长机会

  • 成长机会 1：NDD 侦测与管理护理点智慧诊断
  • 成长机会2：NDD综合评估的综合诊断方法
  • 成长机会3：NDD领域的外泌体组学和代谢体学

附录

  • 技术成熟度等级 (TRL)：解释

下一步

  • 成长机会的好处和影响
  • 下一步
  • 下一步
  • 免责声明
简介目录
Product Code: DAED

Leveraging integrated and point-of-care diagnostics with multiomics represents the most promising growth opportunity to advance molecular diagnostics for neurodegenerative diseases

Neurodegenerative diseases (NDD) pose significant challenges to healthcare systems and affect millions of people worldwide, making early detection crucial. While the current diagnostic strategy is predominantly brain imaging techniques, it is not performed until symptoms are more pronounced. Subtle changes occurring in neural cells during early progression cannot be detected by the structural or functional changes associated with NDDs.

This study is a comprehensive analysis that explores technological advancements, industry dynamics, strategic insights, and growth opportunities in molecular diagnostics for NDDs. It captures the role of leading companies, growing start-ups, and smaller companies with innovative product portfolios and an industry presence, key drivers and restraints, and strategic partnerships. The study also delves into funding, grants, mergers and acquisitions (M&As), and commercialization efforts.

Overall, this study aims to provide insights into the evolving landscape of molecular diagnostics for NDDs and implications for healthcare innovation and patient care.

Key Questions the Study Answers:

1. What are the different molecular diagnostics for NDDs?

2. What are the main challenges and complexities in the widespread adoption of molecular diagnostics compared to imaging diagnostics?

3. What are the primary sources of biomarkers used in NDDs? Who are the key and emerging participants in terms of innovation and technology in this space?

4. How are omics technologies, smart PoC devices, and exosome-mediated diagnoses emerging as novel molecular diagnostics modalities for NDDs? How do they improve accuracy?

5. What are the strategic implications of the emerging collaborations and M&As between academia and industry participants?

6. How do patents contribute to advancements in diagnostics and therapeutics for NDDs?

7. What are the growth opportunities for molecular diagnostics for NDDs?

Table of Contents

Strategic Imperatives

  • Why Is It Increasingly Difficult to Grow?
  • The Strategic Imperative 8™
  • The Impact of the Top 3 Strategic Imperatives on Molecular Diagnostics for the Neurodegenerative Diseases Industry
  • Growth Opportunities Fuel the Growth Pipeline Engine™
  • Research Methodology

Growth Opportunity Analysis

  • Dementia Disease Burden Forecast for 2050
  • Insights into NDD Research: Trends in Publications and Clinical Trials, 2019-2024
  • NDDs: Overview and Importance of Early Diagnosis
  • Segmentation
  • Challenges in Early NDD Diagnosis
  • Diagnostic Modalities in the NDD Landscape
  • Sources of NDD Molecular Biomarkers
  • Scope of Analysis
  • NDD Diagnosis: Biomarker Sources, Sample Extraction, and Analytes
  • Biomarker Sources: A Comparative Analysis
  • Integrated Landscape of NDD Biomarkers

Growth Generator

  • Growth Drivers
  • Growth Restraints

Technology Analysis: CSF Biomarkers

  • CSF-based Molecular Diagnostics to Detect NDDs
  • Key Companies Developing CSF-based Molecular Diagnostics for NDDs
  • Key Biomarkers for Neurodiagnostics: CSF-based Biomarkers, Global, 2024

Technology Analysis: Blood Biomarkers

  • Blood-based Biomarkers in NDD Diagnosis
  • Key Companies Developing Blood-based Molecular Diagnostics for NDDs
  • Emerging Companies Developing Blood-based Molecular Diagnostics for NDDs
  • Key Biomarkers for Neurodiagnostics: Blood-based Biomarkers, Global, 2024

Technology Analysis: Salivary Biomarkers

  • Salivary Biomarkers: An Accessible and Painless Diagnostic Approach for NDDs
  • Emerging Companies Developing Saliva-based Molecular Diagnostics for NDDs

Technology Analysis: Urinary Biomarkers

  • Urinary Biomarkers for Early Diagnosis of NDDs
  • Emerging Companies Developing Urine-based Molecular Diagnostics for NDDs

Technology Analysis: Ocular Biomarkers

  • Ocular Biomarkers: A New Frontier in NDD Diagnosis
  • Neurobiomarkers: Molecular Alterations in the Ocular Space
  • Emerging Companies Developing Ocular-based Molecular Diagnostics for NDDs

Technology Analysis: Skin-based Biomarkers

  • Skin-based Biomarkers for NDDs

Summary of Key Biomarkers for NDD Molecular Diagnostics

  • Key Insights: Biomarker Utilization by Industry Participants in the NDD Diagnostics Space
  • Molecular Biomarkers: From Bench to Clinic, Impact Analysis

Clinical Trial Analysis

  • Notable Clinical Trials in NDD Molecular Diagnostics
  • European Platform for Neurodegenerative Disorders (EPND): A Collaborative Approach to Data and Sample Sharing

Emerging Trends in NDD Molecular Diagnostics

  • Databases and Biobanks: Catalysts for Biomarker Discovery in NDD Diagnosis
  • Epigenetic Alterations as NDD Biomarkers
  • Big Data-powered Multiomics for NDD Diagnosis
  • Exosomes: A Potential Candidate for Early NDD Diagnosis
  • Portable Molecular Diagnostic Devices Enabling Smart Diagnostics for NDDs

Key Participants' Strategic Recommendations

  • Synaps Dx, US
  • AgenT Biotech, France
  • Urvogelbio, India
  • Resonant, US
  • Neurodex, US

Stakeholder Initiatives

  • Notable NDD Diagnostics Collaborations and Clinical Alliances
  • Recent NDD Diagnostics Mergers and Acquisitions
  • Global Companies in NDD Diagnostics: Insight into Regional Adoption

Funding Analysis

  • Snapshot of Public Funding for Molecular Diagnostics of NDDs in the US, 2019-2024
  • Special Focus on NIH Funding for Molecular Diagnostics of AD, 2019-2024
  • EU R&D Projects, 2019-2023
  • Snapshot of Private Funding for Molecular Diagnostics of NDDs, 2021-2024
  • Snapshot of Private Funding for Molecular Diagnostics of NDDs, 2020-2023

Patent Analysis

  • IP Trends in the Molecular Neurobiomarker Industry, 2019-2024
  • Patents by Key Participants in the NDD Diagnostics Space, 2019-2024
  • Analysis of IP Trends in the Molecular Neurobiomarker Industry, 2019-2024

Analyst Perspectives

  • Molecular Diagnostics in NDDs: Technology, Innovation, and Application Impact Analysis
  • Commercial Availability of Different Molecular Diagnostic Technologies in the NDD Landscape
  • Molecular Diagnosis of NDDs: A Technology Road Map

Growth Opportunities

  • Growth Opportunity 1: Smart Diagnostics at the Point of Care for NDD Detection and Management
  • Growth Opportunity 2: Integrated Diagnostics for Comprehensive NDD Assessment
  • Growth Opportunity 3: Exosomics and Metabolomics in the NDD Space

Appendix

  • Technology Readiness Levels (TRLs): Explanation

Next Steps

  • Benefits and Impacts of Growth Opportunities
  • Next Steps
  • Take the Next Step
  • Legal Disclaimer